Page 3 - Ben Atwell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients —

Hong kongUnited statesAtholl tweedieZhou yiBen atwellSingle institution studyAmerican cancer societyStock exchange of hong kongChina national medical products administrationExchange commissionEuropean lung cancer congress onEuropean lung cancer congressNational reimbursement drug listWorld health organizationChina limitedInternational agency for research on cancer

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients If.

Hong kongUnited statesBen atwellZhou yiAtholl tweedieChina limitedEuropean lung cancer congress onAmerican cancer societyNational reimbursement drug listStock exchange of hong kongEuropean lung cancer congressInternational agency for research on cancerWorld health organizationExchange commissionSingle institution studyChina national medical products administration

PureTech-Founded (PRTC) Akili (AKLI) Reports Positive Results from Shionogi s Phase 3 Clinical Trial of Localized Version of Akili s EndeavorRx

PureTech-Founded (PRTC) Akili (AKLI) Reports Positive Results from Shionogi s Phase 3 Clinical Trial of Localized Version of Akili s EndeavorRx
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRob winderScott kollinsNichole bobbynAkili endeavorrxEric elenkoBen atwellPuretech healthEntity akili incAkili incExchange commissionMinistry of healthService haaShionogi coPublic health emergencyDrug administration

HUTCHMED Announces that Inmagene Exercises Option to

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13).

Hong kongZhou yiBen atwellAtholl tweedie freddyCrossley daphneWeiguo suExchange commissionChina limitedStock exchange of hong kongInmagene biopharmaceuticalsChief executive officerChief scientific officerSecurities litigation reform actStock exchangeHong kong limitedNasdaq hcm

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Hong kongAtholl tweedie freddyBen atwellWeiguo suZhou yiCrossley daphneChina limitedStock exchange of hong kongExchange commissionInmagene exercises optionLicense two drug candidatesInmagene biopharmaceuticalsChief executive officerChief scientific officerSecurities litigation reform actStock exchange